While Ven-anti-CD20 monoclonal antibody (mAb) combinations are established standards of care for both TN and R/R CLL, less is known about the merits of adding an anti-CD20 monoclonal antibody to BTKi as first therapy. Here, IBTK is linked to B-cell chronic lymphocytic leukemia.